Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical

被引：0
|
作者：
West, H. J.
Belt, R. J.
Wakelee, H. A.
Monberg, M. J.
Frye, L. A.
Ye, Z.
Obasaju, C. K.
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Kansas City Canc Ctr, Kansas City, MO USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：393S / 393S
页数：1
相关论文
共 50 条
  • [31] A phase I/II study of pembrolizumab (P) with gemcitabine (G) in patients (Pts) with previously-treated advanced non-small cell lung cancer (NSCLC): Phase I safety results
    Sanborn, Rachel E.
    Duffy, Regan M.
    Fisher, Brenda K.
    Perlewitz, Kelly Shea
    Redmond, William L.
    Koguchi, Yoshinobu
    Fox, Bernard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] GEFITINIB (G) AND PEMETREXED (PEM) AS A FIRST LINE TREATMENT IN PATIENTS WITH EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Yoshimura, N.
    Matsuura, K.
    Mitsuoka, S.
    Asai, K.
    Tochino, Y.
    Kimura, T.
    Nakai, M.
    Mitsukawa, Y.
    Hirata, K.
    Kudoh, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 413
  • [33] Effect of race on the safety and efficacy of pemetrexed (P) therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC)
    Tai, D. F.
    Kulkarni, P.
    Wang, Y.
    Gill, J.
    Obasaju, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] The relationship between the responses to prior systemic therapies and the efficacy of subsequent pemetrexed (Pem) therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Sun, J.
    Oh, D.
    Lee, S.
    Kim, D.
    Im, S.
    Kim, T.
    Lee, J.
    Kim, Y.
    Heo, D. S.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
    Cohen, Martin H.
    Cortazar, Patricia
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (12): : 1352 - 1358
  • [36] A phase II of gemcitabine in advanced non-small cell lung cancer
    Koynov, K
    Tzekova, V
    Mincheva, N
    Scherer, A
    Krejcy, K
    3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 231 - 234
  • [37] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study
    Piantedosi, F. V.
    Caputo, F.
    Mazzarella, G.
    Gilli, M.
    Pontillo, A.
    D'Agostino, D.
    Campbell, S.
    Marsico, S. A.
    Bianco, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 803 - 807
  • [38] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study
    F. V. Piantedosi
    F. Caputo
    G. Mazzarella
    M. Gilli
    A. Pontillo
    D. D’Agostino
    S. Campbell
    S. A. Marsico
    A. Bianco
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 803 - 807
  • [39] Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    Corral Jaime, Jesus
    Gonzalez de la Pena, Miriam
    Alonso, Miriam
    Sanchez Gastaldo, Amparo
    Dolores Mediano, Maria
    Amerigo, Marta
    Enrique Robles, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] A PHASE II CLINICAL TRIAL OF TUMOR TREATING FIELD (TTF) THERAPY CONCOMITANT TO PEMETREXED FOR ADVANCED NON-SMALL CELL (NSCLC) LUNG CANCER
    Pless, M.
    Betticher, D.
    Droege, C.
    Salzberg, M.
    von Moos, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 396 - 396
12345